TRAUMA
Timing of bisphosphonate administration does not affect fracture healing or complications
J Bone Joint Surg Br. 2012 Jul;94(7):956-6090 osteoporotic patients, that have undergone fixation for an intertrochanteric fracture, were randomized to receive oral administration of a bisphosphonate (Risedronate) starting either one week, one month, or three months after surgery. The results demonstrate that the timing of bisphosphonate administration following hip fracture surgery does not affect time to fracture healing or incidence of complications. There were no significant differences between the three groups.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
